Flputnam Investment Management Co. Boosts Stock Holdings in Cardiff Oncology, Inc. $CRDF

Flputnam Investment Management Co. lifted its stake in Cardiff Oncology, Inc. (NASDAQ:CRDF) by 1,008.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 597,233 shares of the company’s stock after buying an additional 543,370 shares during the period. Flputnam Investment Management Co.’s holdings in Cardiff Oncology were worth $1,230,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Baader Bank Aktiengesellschaft bought a new position in Cardiff Oncology during the 2nd quarter worth approximately $32,000. Belpointe Asset Management LLC purchased a new stake in shares of Cardiff Oncology during the first quarter valued at approximately $37,000. Integrity Alliance LLC. purchased a new stake in shares of Cardiff Oncology during the second quarter valued at approximately $41,000. Engineers Gate Manager LP bought a new position in shares of Cardiff Oncology in the second quarter worth approximately $43,000. Finally, Lido Advisors LLC purchased a new position in shares of Cardiff Oncology in the second quarter worth $47,000. Institutional investors own 16.29% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (d-)” rating on shares of Cardiff Oncology in a report on Wednesday, October 8th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $10.83.

Cardiff Oncology Stock Performance

Shares of CRDF stock opened at $2.92 on Tuesday. Cardiff Oncology, Inc. has a fifty-two week low of $1.90 and a fifty-two week high of $4.99. The firm has a market cap of $196.69 million, a P/E ratio of -3.70 and a beta of 1.35. The business’s 50 day moving average price is $2.26 and its 200-day moving average price is $2.64.

Cardiff Oncology (NASDAQ:CRDF) last announced its earnings results on Thursday, November 6th. The company reported ($0.17) EPS for the quarter, beating analysts’ consensus estimates of ($0.20) by $0.03. The company had revenue of $0.12 million during the quarter, compared to the consensus estimate of $0.12 million. Cardiff Oncology had a negative return on equity of 77.21% and a negative net margin of 10,064.27%. As a group, equities analysts predict that Cardiff Oncology, Inc. will post -0.99 EPS for the current year.

Cardiff Oncology Profile

Cardiff Oncology, Inc is a clinical-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. The company is dedicated to the discovery, development and commercialization of novel small-molecule therapies designed to modulate the tumor microenvironment and enhance antitumor immune responses. By focusing on unique immuno-oncology targets, Cardiff seeks to address resistance pathways that limit the effectiveness of existing cancer treatments.

Cardiff’s pipeline comprises several small-molecule immunomodulators in various stages of preclinical and clinical development.